Development and Validation of a Next-Generation Sequencing–Based Multigene Assay to Predict the Prognosis of Estrogen Receptor–Positive, HER2-Negative Breast Cancer
Lists
Only you see this
Abstract
The newly developed and validated NGS-based multigene assay can predict the distant recurrence risk in ER-positive, HER2-negative breast cancer.
BibTeX
@inproceedings{lee2020development,
author = {Han‐Byoel Lee and Sae Byul Lee and Minsu Kim and Sunyoung Kwon and Jeonghee Jo and Jinkyoung Kim and Hee Jin Lee and Han-Suk Ryu and Jong Won Lee and Chungyeul Kim and Jae‐Hwan Jeong and Hyoki Kim and Dong‐Young Noh and In-Ae Park and Sei-Hyun Ahn and Sun Kim and Sungroh Yoon and Aeree Kim and Wonshik Han},
title = {{Development and Validation of a Next-Generation Sequencing–Based Multigene Assay to Predict the Prognosis of Estrogen Receptor–Positive, HER2-Negative Breast Cancer}},
booktitle = {Clinical},
year = {2020},
doi = {10.1158/1078-0432.ccr-20-2107},
}Loading related content...